

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: John A. Lowe :

Examiner: Cybille Delacroix-
Muirheid

APPLICATION NO.: 09/007,268 :

Group Art Unit: 1600/2900

FILING DATE: January 14, 1998 :

TITLE: Fluoroalkoxybenzylamino Derivatives :
of Nitrogen Containing Heterocycles

RECEIVED

OCT 0 9 2001

TECH CENTER 1600/2900

RECEIVED
TECH CENTER 1600/2900
OCT -5 AM 11:42

TERMINAL DISCLAIMER

Commissioner for Patents
Washington, D.C. 20231

Sir:

Pfizer Inc. is the owner of 100% interest in the above-captioned application; and in U.S. Patent No. 5,773,450 to Lowe and Rosen, issued June 30, 1998. Pfizer Inc. hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-captioned application, which would extend beyond the expiration date of the full statutory term of U. S. Patent No. 5,773,450, including any patent term extensions, restorations or adjustments for said patent available under all applicable statutes including 35 U.S.C. §§ 154 through 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of U.S. Patent No. 5,773,450. The owner hereby agrees that any patent so granted on the above-captioned application shall be enforceable only for and during such period that the legal title to it and to the above-identified granted patent shall be commonly owned. This agreement runs with any patent granted on the above-captioned application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the above-captioned application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and 173 of the above-identified granted patent, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that the granted patent expires for failure to pay a maintenance fee, is held unenforceable and/or invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR § 1.321, has all claims cancelled by a

09/007,268 Terminal Disclaimer
October 4, 2001
page 2


reexamination certificate, is reissued, or its term is in any manner shortened prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

This Terminal Disclaimer is accompanied by a Fee Transmittal Sheet authorizing payment of the appropriate fee under 37 C.F.R. § 1.20(d).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,

Date: October 4, 2001


Paul H. Ginsburg
Reg. No. 28,718
Attorney of Record

Pfizer Inc. Legal Department
235 East 42nd Street – 20th Floor
New York, New York 10017-5755
(212) 733-2369